科研动态PubMed 摘要

美国癌症协会2026年前列腺癌早期检测指南。

PubMed 白名单日捞 · 2026-01-01

完整摘要 · 中文译文

前列腺癌筛查的目标是通过早期发现具有临床意义的疾病来降低发病率和死亡率。越来越多的证据表明,基于前列腺特异性抗原(PSA)的筛查可显著降低前列腺癌死亡率和晚期诊断率,且减少筛查相关危害的方法正日益得到应用。美国癌症协会(ACS)开展了一项系统综述并委托了一项建模研究以评估基于PSA的筛查策略,结论是筛查的获益大于危害。在启动筛查之前,临床医生应确保患者了解筛查的获益、局限性和危害;PSA水平升高时可能的后续评估;以及对低风险癌症初始采用主动监测管理的预期。ACS建议对平均风险男性(即无前列腺癌家族史的非黑人男性)从50至69岁每两年筛查一次。建议黑人男性从45至69岁每年筛查一次。建议有强家族史的非黑人男性(即多名一级亲属在任何年龄被诊断为前列腺癌,或一名一级亲属在65岁前被诊断)从45至69岁每年筛查一次。建议有一名一级亲属在65岁或以上被诊断的非黑人男性从45至69岁每两年筛查一次。对于70至74岁的男性,获益与危害的平衡尚不确定,建议个体化决策。ACS建议进一步评估 年龄45-69岁且PSA水平≥3.0 ng/mL的男性,以及年龄70-74岁且PSA水平≥6.5 ng/mL的男性。大多数在重复检测中确认PSA水平升高的男性应接受磁共振成像和/或经过验证的生物标志物检测,以指导活检决策。不建议对预期寿命<10年的男性进行筛查,并应在75岁时停止筛查。

完整摘要 · 英文原文

The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate-specific antigen (PSA)-based screening significantly reduces prostate cancer mortality and advanced-stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA-based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow-up evaluations of elevated PSA levels; and the expectation that low-risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50-69 years for average-risk men (i.e., non-Black men without a family history of prostate cancer). Annual screening from ages 45-69 years is recommended for Black men. Annual screening from ages 45-69 years is recommended for non-Black men with a strong family history (i.e., multiple first-degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45-69 years is recommended for non-Black men with a single first-degree relative diagnosed at age 65 years or older. For men ages 70-74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45-69 years with PSA levels ≥3.0 ng/mL and men ages 70-74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy <10 years and should be discontinued at age 75 years.

English
American Cancer Society guideline for the early detection of prostate cancer, 2026.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界